Stina Wallmark

Good news for Bioxodes and its treatment for haemorrhagic stroke. Following promising results from the Phase 2a clinical trial, Bioxodes can move on to a new phase and aims to bring the product to market before 2030. Marc Dechamps, Chief Executive Officer of Bioxodes: “We are in discussions with prospective investors and partners to support the launch of a potentially registrational Phase 2b trial of BIOX-101 to treat intracerebral hemorrhage. Given the high unmet medical need in ICH and Orphan Drug Designations for BIOX-101 in both the U.S. and EU, we believe this breakthrough therapeutic candidate can come to market as early as 2030.” 👉 Read the full release: https://lnkd.in/eyXTrXY9 👉 Read the full article: https://lnkd.in/e3EprXvY

190

9 kommentarer

"We are creating a manufacturing pathway that allows tissue therapies to be scaled, industrialized, and ultimately commercialized—bridging the gap that has long limited the field of advanced therapies." says VERIGRAFT CEO, Petter Bjorquist. The Swedish biotech is solving one of the biggest challenges in regenerative medicine: Making personalized tissue therapies industrially scalable. It's P-TEV technology creates patient-specific engineered veins to cure chronic venous insufficiency—currently an incurable condition. With successful Phase I/IIa trials completed, VERIGRAFT is advancing to Phase II studies. The company is also expanding its platform into additional vascular indications to maximize commercial potential. The company's hybrid manufacturing model keeps critical IP in-house while partnering with CDMOs for scale.

38

3 kommentarer

Induced pluripotent stem cells (iPSCs) are unlocking new possibilities in regenerative medicine. At OmniaBio, we bring deep expertise in developing and manufacturing scalable, reliable iPSC therapies, accelerating access for patients and advancing the future of healthcare.   Learn more about our capabilities: https://omniabio.com/ipsc/   #iPSC #CellAndGeneTherapy #Biomanufacturing #RegenerativeMedicine #AccessForAll 

136

2 kommentarer

Last week we announced a major order with a global pharma company, partnering with Biosero to accelerate their drug development process through lab automation. This collaboration reflects a growing trend - leading pharma companies are turning to automation to drive efficiency, consistency, and innovation in their R&D pipelines. Whether screening vast compound libraries or optimizing lead candidates, automation delivers speed, scale, and reproducibility, so scientists can focus on finding the next breakthrough. Here’s how automation transforms drug discovery: • Screen smarter: Boost throughput and data quality across every assay • Reduce bottlenecks: Minimize manual steps in hit-to-lead workflows • Scale with confidence: Standardize processes for consistent, reproducible results Discover how Biosero can help accelerate your drug discovery workflows: https://lnkd.in/djrw9i3Q #LabAutomation #BICO #LaboftheFuture

53

Another Major Move in the MASH Landscape: Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion. Novo Nordisk’s planned acquisition of Akero Therapeutics marks one of the largest deals yet in the metabolic liver disease space, underscoring the growing momentum around MASH (Metabolic dysfunction-Associated Steatohepatitis). Akero’s lead candidate, efruxifermin (EFX), has shown promise in improving fibrosis and resolving MASH across multiple Phase 2 studies and is now being tested in three global Phase 3 trials. By bringing Akero into its portfolio, Novo Nordisk strengthens its position beyond GLP-1–based therapies, expanding into fibrosis reversal and advanced-stage liver disease, where few options exist today. This acquisition highlights how major industry leaders are investing heavily in metabolic-liver innovation, recognizing the interconnected nature of obesity, diabetes, and MASH, and the urgent need for treatments that address these overlapping diseases. If completed, this deal could help accelerate global access to new therapies and signal a pivotal step toward integrated care models for patients with metabolic dysfunction and liver disease. #MASLD #MASH #LiverHealth #MetabolicHealth #FattyLiver American Association for the Study of Liver Diseases (AASLD), EASL | The Home of Hepatology, European Liver Patients'​ Association - ELPA https://lnkd.in/gD6y6kpY

32